LINCOLN, Neb. (KLKN) – The Food and Drug Administration approved the pancreatic cancer drug Daraxonrasib on Wednesday, months ahead of schedule. The drug is an oral medication that is taken once a day. It targets the protein responsible for ramping up pancreatic cancer cells in the body. The patie nts who took part in the clinical trials, such as former Nebraska... ...read more read less